Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company focused on developing and commercializing innovative medicines for treating patients with acute and chronic pain, as well as attention deficit hyperactivity disorder (ADHD). The company's primary activities include the development, licensing, and acquisition of differentiated products for ADHD and moderate to severe pain treatment.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Collegium is dedicated to advancing its research and development efforts to improve the lives of patients with serious medical conditions. The company's R&D initiatives focus on enhancing its existing product portfolio and exploring new therapeutic opportunities in pain management and neuropsychiatry. Key initiatives include the DETERx Technology Platform for developing abuse-deterrent formulations, lifecycle management of products like Xtampza ER, Belbuca, and Nucynta, expansion into neuropsychiatry with products like Jornay PM, pursuing FDA exclusivity extensions for pediatric use, and leveraging strategic collaborations and acquisitions to enhance R&D capabilities. The R&D unit of Collegium is responsible for managing the company's research and development activities, focusing on the development of differentiated products that offer significant clinical benefits over existing therapies. The unit emphasizes innovation in drug delivery technologies, expansion into new therapeutic areas, and addressing the evolving needs of patients and healthcare providers.